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ABSTRAK 
 
Abstrak 
Penyakit permukaan okular kerap dijumpai pada pesakit diabetes melitus. Ia akan 
menjadi lebih teruk akibat dari rawatan laser sama ada secara kontak atau tanpa kontak 
sekiranya pesakit diabetes dikomplikasikan dengan proliferatif diabetik retinopati.  
 
Objektif 
Matlamat kajian ini adalah untuk mengkaji kesan laser secara kontak dan tanpa kontak 
terhadap perubahan permukaan ocular dan skor Indeks Penyakit Permukaan Okular 
(OSDI) pada pesakit proliferatif diabetik retinopati.  
 
Kaedah Kajian 
Kajian ini merupakan kajian terkawal secara rawak yang dijalankan di Hospital 
Universiti Sains Malaysia bermula dari Jun 2013 hingga Mei 2015. Pesakit yang 
menghidapi proliferatif diabetik retinopati telah dipilih dan dibahagikan secara rawak 
kepada 2 kumpulan (kumpulan laser kontak dan kumpulan laser tanpa kontak) dengan 
menggunakan kaedah pensampelan rawak sampul surat. Perubahan permukaan okular 
dinilai melalui ujian Schirmer, masa pemecahan filem air mata (TBUT) dan skor OSDI 
sebelum dan 3 bulan selepas rawatan laser. Analisis data dilaksanakan dengan 
menggunakan SPSS versi 22.0. 
 
Keputusan 
Seramai 60 mata daripada 34 pesakit (kumpulan laser kontak: 30 mata daripada 17 
pesakit dan kumpulan laser tanpa kontak: 30 mata daripada 17 pesakit) telah dipilih 
 xi 
untuk kajian ini. Didapati tiada perbezaan signifikan dalam perubahan purata ujian 
Schirmer (p=0.378) selepas 3 bulan rawatan laser antara kedua-dua kumpulan. 
Walaupun terdapat peningkatan signifikan ujian TBUT selepas 3 bulan rawatan laser 
bagi kumpulan laser kontak (p=0.038), tetapi tiada perbezaan signifikan dalam 
perubahan purata ujian TBUT di antara kedua-dua kumpulan (p=0.549). Didapati 
perubahan purata skor OSDI menunjukkan peningkatan yang signifikan pada 3 bulan 
selepas rawatan laser bagi kumpulan laser kontak berbanding dengan kumpulan laser 
tanpa kontak (p=0.044).   
 
Kesimpulan   
Rawatan laser secara kontak menyebabkan perbezaan semakin teruk yang signifikan 
untuk ujian TBUT dan peningkatan skor OSDI. Namun begitu, laser tanpa kontak tidak 
semestinya mengurangkan kesan ke atas permukaan okular pada pesakit diabetik 
retinopati. Langkah penjagaan yang sewajarnya perlu diambil untuk menjaga 
permukaan okular untuk pesakit diabetik retinopati semasa rawatan laser.   
 xii 
ABSTRACT 
 
Introduction 
Ocular surface changes are commonly seen in diabetes mellitus. It can be made worse 
by either contact or non-contact laser photocoagulation (LP) in proliferative diabetic 
retinopathy (PDR).  
 
Objective  
The aim of the study is to evaluate the effects of contact and non-contact LP therapy on 
ocular surface changes and Ocular Surface Disease Index (OSDI) score in patients with 
PDR. 
 
Methods 
This is a randomized controlled trial in Hospital Universiti Sains Malaysia from June 
2013 to May 2015. Patient with PDR was selected and randomized into 2 groups by 
using random sampling envelope method, Contact LP group and Non-contact LP group. 
Patients were evaluated for Schirmer test, tear film break-up time (TBUT) and 
assessment of OSDI questionnaire before treatment and 3 months post laser treatment. 
Statistical analyses were performed using SPSS version 22.0.  
 
Results 
A total of 60 eyes from 34 patients were recruited (Contact LP: 30 eyes from 17 patients 
and Non-contact LP: 30 eyes from 17 patients). There was no significant difference in 
mean change of the Schirmer test (p=0.378) at 3 months post treatment between the two 
groups. Although there was significant reduction in TBUT at 3 months post laser in 
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Contact LP group (p=0.038), but there was no significant difference in mean change of 
TBUT between the two groups (p=0.549). There was significant increased in mean 
change of OSDI score at 3 months post treatment in Contact LP group as compared to 
Non-contact LP group (p=0.044).  
 
Conclusion 
Contact LP resulted in significant worsening of TBUT and increasing in OSDI sore. 
However, non-contact LP may not minimize the effect of laser on ocular surface of 
diabetic retinopathy patients. Appropriate care should be given to the ocular surface of 
diabetic retinopathy patients during LP procedure. 
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CHAPTER 1 
INTRODUCTION 
 
Diabetic retinopathy is a progressive dysfunction of the retinal vasculature caused by 
chronic hyperglycemia. As the prevalence of type 2 diabetes mellitus rises, so do its 
attendant, microvascular complications.  
 
Based on the Malaysia First Annual Report of the National Eye Database in 2007, the 
level of severity of diabetic retinopathy among eyes examined showed that 23.1% had 
mild to moderate non-proliferative diabetic retinopathy (NPDR), 3.0% had severe 
NPDR, and 6.2% had proliferative diabetic retinopathy (PDR), of which 2.0% was at 
advanced diabetic eye disease state (Goh et al., 2007). Diabetic retinopathy is a chronic 
and potentially sight-threatening disease. It is the major cause of blindness in persons 
less than 30 to 69 years of age in developed countries (Watkins, 2003). 
 
Several studies (Moss et al., 2000; Kaiserman et al., 2004) have shown that dry eye 
syndrome is more common among diabetic patients. International Dry Eye Workshop 
(DEWS) recently agreed the latest definition of dry eye as a multifactorial disease of 
tears and ocular surface that results in symptoms of discomfort, visual disturbance and 
tear film instability with potential damage to the ocular surface. It is accompanied by 
increased osmolarity of the tear film and inflammation of the ocular surface. One study 
has shown that the degree of keratoepitheliopathy was severe, and the corneal 
sensitivity, tear film break-up time and tear secretion were significantly reduced in the 
diabetic patients (Yoon et al., 2004). 
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Laser photocoagulation (LP) has become a valuable modality to treat diabetic 
retinopathy. The Diabetic Retinopathy Study (DRS) found that its use in panretinal 
photocoagulation has been shown to be resulted in more regression of 
neovascularization in PDR. Nevertheless, LP therapy is not without complications. It is 
reported that a statistically significant change in endothelial cell density in the six-week 
follow-up post laser therapy (Pardos et al., 1981). A study in evaluating the effect of 
coupling solutions used during LP on the ocular surface of patients with type 2 diabetes 
mellitus was done and they concluded that the use of viscous coupling solutions during 
applanation contact lens-aided laser procedures may be detrimental for the corneal 
epithelium in poorly controlled diabetic pateints (Dogru et al., 2004). 
 
LP is one of the risk factors for ocular surface disease in diabetic retinopathy (Ozdemir 
et al., 2003). In contact LP, direct contact of the laser contact lens and coupling fluid 
onto the ocular surface can cause direct trauma to the cornea, and this is made worse by 
friction during manipulation of the laser contact lens. On the other hand, while 
delivering non-contact LP, the eye is kept opened by a speculum and this could expose 
the cornea and lead to excessive dryness of the ocular surface.  
 
The aim of this study is to evaluate the effects of contact LP and non-contact LP 
towards ocular surface disease in PDR.   
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1.1 Background 
1.1.1 Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder of multiple etiology characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both. Diabetes mellitus is diagnosed 
when the fasting blood sugar level (venous) is more than 6.1 mmol/L or when 2-hour 
post glucose load (venous) is more than 10.0 mmol/L.  
 
The long term effects of diabetes mellitus include macrovascular complications such as 
cardiovascular, peripheral vascular and cerebrovascular disease, and microvascular 
complications include retinopathy which can potentially lead to blindness, nephropathy 
and neuropathy.  
 
 
1.1.2 Diabetic Retinopathy 
One of the microvascular complications of diabetes mellitus is diabetic retinopathy 
which gained great popularity among researchers. Diabetic retinopathy is a major cause 
of acquired blindness in adults. Extended period of exposure to hyperglycemia leading 
to vascular endothelial damage which subsequently causing retinal capillary changes. 
Diabetic retinopathy has been classified according to the guidelines set out by the Early 
Treatment Diabetic Retinopathy Study (ETDRS) and the Diabetic Retinopathy Study 
(DRS). Based on EDTRS, diabetic retinopathy is classified into mild, moderate and 
severe nonproliferative diabetic retinopathy (NPDR) and PDR (ETDRS, 1991).  
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1.1.3 Proliferative Diabetic Retinopathy 
PDR is a microangiopathy leading to microvascular occlusion and leakage, 
subsequently retinal hypoxia which may cause neovascularization on retina and optic 
disc, and occasionally new vessels formation on the iris. PDR can be further subdivided 
into 
i) Early PDR with definite neovascularization 
ii) High risk PDR with any one of the following: 
a. 1/4 to 1/3 disc area of neovascularization of the optic disc (NVD) 
with vitreous hemorrhage 
b. 1/2 disc area or more of NVD with or without vitreous hemorrhage 
c. 1/2 disc area of neovascularization elsewhere (NVE) with vitreous 
hemorrhage 
 
The gold standard treatment of PDR is panretinal laser photocoagulation. 
 
 
1.1.4 Laser Photocoagulation 
Laser is an acronym for light amplification by stimulated emission of radiation. Laser 
photocoagulation (LP) is the mainstay of treatment for PDR. Laser therapy in PDR 
takes the form of pan-retinal photocoagulation (PRP), in which perhaps 2000-3000 
large burns are applied to retina outside the central thirty-degree zones. This tends to 
encourage a reduction in the caliber of new vessels. PRP is effective in producing a 
“quiescent” retina. There are two methods of LP delivery, which is the contact LP via 
slit lamp laser system, and non-contact LP via laser indirect ophthalmoscopy (LIO) 
system.  
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1.1.4.1 Contact Laser Photocoagulation 
Contact LP denotes the conventional way of LP whereby laser via the slit-lamp 
biomicroscope and the delivery of Argon green laser is transcorneal. Laser is delivered 
to the retina using the Mainster Wide Field contact lens and Goldmann’s three-mirror 
contact lens with the patient sits at a slit-lamp with laser fibreoptic cable. 
 
Advantages of contact LP are during delivering of laser, the operator will have more 
precision and control, especially when treating around the vessels arcade and optic 
nerve. In addition, more stability can be achieved with the aid of laser contact lens in 
cases of wandering eye movements. Laser contact lens can also help in stabilization of 
the lids for those with excessive blepharospasm (Minarcik et al., 2010). 
 
 
1.1.4.2 Non-contact Laser Photocoagulation 
The indirect ophthalmoscope with a condensing lens also may be used transcorneally to 
photocoagulate the posterior segment. LP is delivered to retina with the aid of a 20D or 
30D condensing lens. There is no direct contact of the condensing lens with patient’s 
eye hence no coupling fluid used. Patient’s eye will be held open by wire speculum and 
intermittently the cornea must be moistened by applying artificial tears eyedrops. 
 
Indirect non-contact LP treatment provides a better view of the whole fundus as 
compared to slit lamp contact laser system. This significantly reduces the time for 
panretinal photocoagulation (Mizuno, 1981). It can also be used to treat eyes with 
partial vitreous hemorrhage and suitable for patients with various medical and 
psychological conditions preventing adequate contact laser treatment (Gurelik et al., 
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2004). In cases of small pupil, the operator can perform LP better with the aid of a 28D 
lens (Minarcik et al., 2010). 
 
Disadvantage of non-contact LP is the requirement of placement of eye speculum which 
keeps the eye opened, thus exposing to the risk of ocular surface dryness during the 
procedure.  
 
 
1.1.5 Ocular Surface Disease and Diabetes Mellitus 
Ocular surface is a biological continuum of three major regions, the cornea, limbus and 
conjunctiva. Ocular surface disease is a constellation of inflammatory disorder 
involving eyelid, eyelashes, lacrimal gland, tear film, conjunctiva and cornea.  
 
The ocular surface disease in diabetes is characterized by a disorder of tear quantity and 
quality, squamous metaplasia, and goblet cell loss (Dogru et al., 2000). Ozdemir et al 
studied on the risk factors for ocular surface disease in diabetic patients, and found that 
laser PRP, poor metabolic control and PDR are high risk factors for tear dysfunction 
and ocular surface disease (Ozdemir et al., 2003).  
 
The prevalence of ocular surface disease in diabetes mellitus is higher than normal 
populations (Saprafka et al., 1990; Kaiserman et al., 2005; Cousen et al., 2006). 
Diabetes mellitus is commonly associated with dry eye disease (Manaviat et al., 2008; 
Burda et al., 2013). Every layer of the cornea was shown to have changes in diabetic 
eyes, starting from the epithelial cells which demonstrate punctate epitheliopathy, 
persistent epithelial defect and delayed healing (Schultz et al., 1981; Chikama et al., 
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2007), abnormally fragile epithelium (O’Leary et al., 1981), thickened epithelial 
basement membrance (Azar et al., 1992) and abnormal morphologic characteristics in 
corneal endothelial cells (Larsson et al., 1996). Decreased corneal sensitivity is also 
commonly seen in diabetic cornea (Ruben, 1994; Saito et al., 2003; Yoon et al., 2004; 
Cousen et al., 2007, Neira-Zalentein et al., 2011). Diabetic patients often have 
decreased Schirmer test measurement and tear film instability as demonstrated by 
reduced TBUT (Goebbels, 2000; Dogru et al., 2004; Cousen et al., 2007; Rahman et al., 
2007; Burda et al., 2012; Burda et al., 2013).  
 
 
1.1.6 Ocular Surface Disease Associated with Laser Photocoagulation 
Panretinal LP is the treatment for PDR performed in the clinic setting. A total of 1500-
2000 burns were applied in one or more treatment sessions under direct visualization of 
the retina (Klein et al., 1997). Prompt treatment is advisable and effective in retarding 
much of the morbidity associated with PDR (DRS, 1981). However, it is associated 
with various risks and complications (Zweng et al., 1974; Little, 1976). Effects of LP 
towards anterior segment such as severe degree of striate keratopathy with Descemet’s 
membrane fold was well documented (Kanski, 1975). When laser power used is too 
high, it can cause damage to the cornea and lens (Peyman et al., 1984). Breakdown of 
blood-aqueous barrier with significant increase in aqueous flare was also found after 
retinal laser treatment and it persisted to a lesser extent after 3 months (Larsson et al., 
2001). 
 
A study found that the use of viscous coupling solutions during applanation contact-
lens-aided laser procedures may be detrimental for the corneal epithelium in poorly 
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controlled non-insulin dependent diabetes mellitus patients with peripheral neuropathy 
and coexisting aqueous deficiency (Dogru et al., 2004). They postulated that it might be 
the greater friction on the ocular surface caused by more viscous agents during 
rotational maneuvers of the applanation contact lenses inflicts more damage to the 
basement membrane in aqueous-deficient diabetic eyes. 
 
During non-contact LP, there’s no direct manupilation of the ocular surface. However, 
the eye is kept opened by a speculum throughout the procedure and this could expose 
the cornea and lead to excessive dryness of the ocular surface.  
 
Traditionally, PDR has been managed with slit lamp laser system with the usage of 
contact lens. Many practitioners use slit lamp laser system when treating PDR. A survey 
showed that 91% of respondents used slit lamp contact laser system, as compared to 
only 9% used binocular indirect non-contact laser (Pollack, 2003). Both methods of LP 
are effective and results in stabilization of PDR (Gurelik et al., 2004). However, LP can 
generate a further impairment in the ocular surface and corneal sensitivity (Ozdemir et 
al., 2002; Dogru et al., 2004; Neira-Zalentein et al., 2011).  
 
Patients with ocular surface disease often presented with a wide range of complains, 
ranging from redness of the eye, grittiness, foregin body sensation, photophobia to 
blurred vision (Sayin et al., 2015). 
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1.1.7 Assessment of Ocular Surface Disease 
Evaluation of ocular surface disease can be performed using Schirmer test, tear film 
break-up time (TBUT), cornea staining with fluorescein or Rose Bengal stain, tear 
osmolarity, symptom questionnaire and many more (Dogru et al., 2004; Yoon et al., 
2004; Rahman et al., 2007; Figueroa-Ortiz et al., 2011). 
 
In this study, Schirmer test, TBUT and Ocular Surface Disease Index (OSDI) 
questionnaire were employed to assess the ocular surface changes. 
 
 
1.1.7.1 Schirmer Test 
Schirmer test is a simple and noninvasive office procedure to evaluate the quantity of 
the tear film by using filter paper. It was first decribed by Schirmer in 1903 and 
subsequently many variants in the technique were introduced in regards to the type of 
paper, position of the filter paper, with or without anesthesia.  
 
Schirmer test with topical anesthesia (proparacaine hydrochloride 0.5%) is performed 
with standardized strips of filter paper. The anesthetic is thought to eliminate the reflex 
tearing produced by irritation from the filter paper, and wetting of the filter paper 
thought to represent basal tear secretion.  
 
Previous studies noted that the Schirmer test results were significantly lower in diabetic 
patients (Dogru et al., 2000; Yoon et al., 2004). It was found that Schirmer test values 
averaged 7.40 ± 0.38 mm in diabetic patients versus 13.53 ± 0.50 mm in the control 
subjects (p<0.001); Schirmer test results were also lower in patients with poorly 
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controlled diabetes compared with diabetes with good control (p<0.001) (Dogru et al., 
2000).  
 
 
1.1.7.2 Tear Film Break-up Time (TBUT) 
TBUT is commonly known as one of the most effective, simplest and noninvasive test 
for diagnosing dry eye disease. It has high reproducibility (95%) in dry eye patients 
(Lee et al., 1988). TBUT is a simple test to measure the relative stability of the 
precorneal tear film. It is performed with moistened fluorescein strips being introduced 
to the conjunctival sac with minimal stimulation. The subjects will be instructed to blink 
several times. TBUT is measured from the time interval between a complete blink and 
the formation of the first dry spot in the precorneal tear film after instillation of the 
fluorescein (Savini et al., 2008). Few studies noted that there was statistically 
significant reduced in TBUT in diabetic patients as compared to control subjects (Dogru 
et al., 2000; Li et al., 2004).  
 
 
1.1.7.3 Ocular Surface Disease Index (OSDI) 
Ocular surface disesase can be evaluated subjectively by questionnaires The Ocular 
Surface Disease Index (OSDI). This questionnaire is developed by the Outcomes 
Research Group at Allergan Inc (Irvine, Calif). It is a 12-item questionnaire designed to 
provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye 
disease and their impact on vision-related functioning.  
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The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater 
disability. The index demonstrates sensitivity and specificity in distinguishing between 
normal subjects and patients with dry eye disease.  
 
OSDI =   
   
 
OSDI demonstrates both high internal consistency and good to excellent test-retest 
reliability in between patients with dry eye disease and normal controls. Other than that, 
OSDI also demonstrates excellent validity, effectively discriminating between normal, 
mild to moderate, and severe dry eye disease (Schiffman et al., 2000).  
 
The OSDI is a valid and reliable instrument for assessing severity of dry eye disease and 
it shows good sensitivity and specificity in distinguishing between normal subjects and 
dry eye patients (Schiffman et al., 2000). Patients can be classified into normal (OSDI 
score less than 12), mild (13-22), moderate (23-32) or severe dry eye disease (score 33 
or more) (Schiffman et al., 2000). The translated Malay version of OSDI questionnaire 
was used in this study. The translated version was validated and conducted for study to 
assess patient with dry eyes [(Fadzillah MT. The Effect of Omega 3 on Dry Eye Disease, 
of dissertation submitted as partial fulfillment for the degree of Master of Medicine 
(Ophthalmology), Universiti Sains Malaysia 2013)]. Reliability of total items and 
subcategory were good with Cronbach alpha value of more than 0.7 in the mentioned 
study. 
(sum of scores) x 25 
number of questions answered 
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1.2 Rationale of Study 
Several clinical and experimental studies have reported structural, metabolic, and 
functional abnormalities in the cornea of diabetic patients (Azar et al., 1992; Larsson et 
al., 1996; Dogru et al., 2001; Chikama et al., 2007; Cousen et al., 2007; Hasan, 2010; 
Fuerst et al., 2014). Diabetic patient are at higher risk of developing ocular surface 
disease as well as diabetic keratopathy.  
 
Epithelial fragility, microcystic edema, superficial punctate keratopathy, persistent 
epithelial defects, recurrent corneal erosions, decreased corneal sensitivity, neurotrophic 
corneal ulceration, dry eye, filamentary keratitis, and Descemet fold constitute the range 
of diabetic corneal complications.  
 
Friction from manipulation of laser contact lens and coupling fluid used during contact 
LP on the ocular surface may be detrimental for the corneal epithelium in poorly 
controlled non-insulin dependent diabetes mellitus. In non-contact LP, the eye is kept 
opened by a speculum throughout the procedure and this could expose the cornea and 
lead to excessive dryness of the ocular surface. Both contact and non-contact LP 
procedure could worsen the pre-existing diseased cornea and lead to devastating 
sequelae such as infective keratitis. Thus, it is important for clinician to understand this 
and be more vigilant in order to prevent the complications. 
 
The aim of this study is to evaluate the effects of contact LP and non-contact LP 
towards ocular surface disease in PDR.  
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CHAPTER 2 
RESEARCH OBJECTIVES 
 
2.1 General Objective 
 
To evaluate the effects of contact and non-contact LP therapy on signs and symptoms of 
ocular surface in patients with PDR. 
 
2.2 Specific Objectives 
 
1) To compare the mean change (baseline and three months post treatment) in 
Schirmer measurement between contact LP and non-contact LP in patients with 
PDR. 
 
2) To compare the mean change (baseline and three months post treatment) in 
TBUT between contact LP and non-contact LP in patients with PDR. 
 
3) To compare the mean change (baseline and three months post treatment) in 
OSDI score between contact LP and non-contact LP in patients with PDR. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Study Design 
Randomised controlled trial 
 
 
3.2 Place of Study 
Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan 
 
 
3.3 Study Duration 
June 2013 to May 2015 
 
 
3.4 Study Population 
All diabetic patients with PDR presented to Hospital Universiti Sains Malaysia. 
 
 
3.5 Ethical Board Approval 
This study was approved by the Research and Ethical Committee, School of Medical 
Sciences, Universiti Sains Malaysia on 29th May 2013 (Appendix A).  
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3.6 Financial Support 
This study did not receive any financial grant or support from any party. 
 
 
3.7 Sample Size 
This is a pilot study. Sample size is 30 eyes in each group. 
 
 
3.8 Sampling Method 
Universal sampling was used in which all Type 2 Diabetic Mellitus patients diagnosed 
with PDR attending Eye Clinic, Hospital Universiti Sains Malaysia from June 2013 till 
May 2015 that fulfill the inclusion criteria and exclusion criteria were recruited into the 
study. 
 
 
3.9 Randomization 
New cases of PDR who fits the eligible criteria and consented for the study were 
randomized into two groups using random sampling envelope technique. A stack of 
opaque envelope were prepared with half of the envelopes containing a piece of paper 
with the word “CONTACT LP” and the remaining halves stated “NON-CONTACT 
LP”. These envelopes were shuffled and drawn for each patient. This was performed 
after the baseline parameters had been taken.  
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3.10 Selection Criteria 
All patients were assigned into two groups, Contact LP group and Non-contact LP 
group. 
 
 
3.10.1 Inclusion Criteria 
• Newly diagnosed PDR. 
• Age between 18 to 70 years old. 
 
 
3.10.2 Exclusion Criteria 
• Patients on regular eye drops medication (eg topical antiglaucoma drugs or tears 
supplement) 
• PDR with neovascular glaucoma 
• Poor media that obscuring view of delivering LP to the retina 
a) Corneal opacity 
b) Preretinal or vitreous hemorrhage obscuring view of retina 
• Previous history of intraocular surgery or ocular trauma including chemical, 
thermal or radiation injury 
• Contact lens wearer 
• Previous history of LP 
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3.11 Definition of Terms 
3.11.1 Proliferative Diabetic Retinopathy (PDR) 
PDR is a more serious form of diabetic retinopathy which characterized by presence of 
neovascularization on or within one disc diameter of the disc and/ or neovascularization 
elsewhere in the fundus (ETDRS, 1985).  
 
 
3.11.2 Contact Laser Photocoagulation 
Laser is delivered to the retina using the Mainster Wide Field contact lens and 
Goldmann’s three-mirror contact lens with the patient sits at a slit-lamp with laser 
fibreoptic cable (Dowler, 2003; Minarcik et al., 2010). Laser machine Visulas 532s 
(Carl Zeiss) was used in this study. 
 
 
3.11.3 Non-contact Laser Photocoagulation 
The binocular indirect ophthalmoscope laser delivery system with a 20D, 28D or 30D 
condensing lens is used transcorneally to photocoagulate the posterior segment (Dowler, 
2003; Minarcik et al., 2010). There’s no direct contact of coupling fluid or laser contact 
lens with the ocular surface during the LP procedure. 
 
 
3.11.4 Schirmer test 
Schirmer test with anesthesia is a test to measure basal tear production using Schirmer 
test paper. Readings are reported in millimeters of wetting for 5 minutes. A reading less 
than 5 mm is taken as the cut-off value for abnormal (Dogru et al., 2001).   
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3.11.5 Tear Film Break-up Time (TBUT) 
TBUT is defined as the interval between the last complete blink and the first appearance 
of a dry spot or disruption in the tear film. A TBUT of less than 10 seconds is 
considered abnormal (Rahman et al., 2007). 
 
 
3.11.6 Ocular Surface Disease Index (OSDI) 
Ocular surface disease index (OSDI) is a scoring system based on questionnaire 
consisting of 12 questions with scoring from 4 to 0. Patient is asked regarding visual 
function, ocular symptoms and environmental triggers for the past 1 week.  
 
Based on the conversion chart for OSDI scoring system, patient can be classified into 
normal, mild, moderate or severe dry eye disease. OSDI score less than 12 is considered 
normal, 13-22 for mild, 23-32 for moderate and scoring of 33 or more is considered as 
severe dry eye (Schiffman et al., 2000). 
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3.12 Instrument 
3.12.1 Carl Zeiss Visulas 532s Laser System (Carl Zeiss Meditec AG, Jena, 
Germany) 
This slit lamp laser system (Figure 3.1) is a frequency doubled solid state laser with 532 
nm argon-green laser wavelength. It provides various sizes of laser spot option ranging 
from 50 μm2 to 1000 μm2 without using contact lens.  
 
 
 
Figure 3.1 Carl Zeiss Visulas 532s Laser System 
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3.12.2 Carl Zeiss Visulas LIO 532s/Trion Laser System (Carl Zeiss Meditec 
AG, Jena, Germany) 
Non-contact LP is delivered via this LIO system with the laser console similar to 
contact LP. Binocular indirect ophthalmoscope is being used instead of slit lamp 
biomicroscopy system. LP is delivered to the retina with the aid of a 20D condensing 
lens (Figure 3.2). 
 
 
 
Figure 3.2 Carl Zeiss Visulas LIO 532s/ Trion Laser System 
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3.12.3 Ocular Mainster Wide Field Laser Contact Lens (Ocular Instruments 
Inc., WA, USA) 
Ocular Mainster wide field contact lens (Figure 3.3) was one of the contact lens used for 
LP. It is used with coupling fluid. It provides excellent retinal resolution with 
binocularity across the entire field of view. It offers 118° field of view. The contact 
diameter with ocular surface is 15.5 mm.  
 
 
 
Figure 3.3 Ocular Mainster Wide Field Laser Contact Lens 
 
 
3.12.4 Goldmann’s Three Mirror Laser Contact Lens (Ocular Instruments 
Inc., WA, USA) 
Goldmann’s three mirror laser contact lens (Figure 3.4) with coupling fluid was used to 
deliver LP to the periphery retina. This contact lens has three mirrors angled at 59°, 67° 
and 73° and the center portion of the lens permitting view to the posterior pole. The 
contact diameter with ocular surface is 18 mm.  
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Figure 3.4 Goldmann’s Three Mirror Laser Contact Lens 
 
 
3.12.5 Slit Lamp Biomicroscope (Topcon Corp., Japan) 
The slit lamp biomiocroscope was used to perform detail ocular examination (Figure 
3.5). In this study, it is used to assess the TBUT and also to exclude any pre-existing 
ocular pathology.  
 
 
3.12.6 Fluorescein Sodium Paper Strip (Bio Glo) (HUB Pharma., USA) 
Fluorescein sodium paper strip (Figure 3.6) was used to stain the ocular surface for 
assessment of TBUT.  
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Figure 3.5 Slit Lamp Biomicroscope 
 
 
 
 
Figure 3.6 Fluorescein Sodium Paper Strip 
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3.12.7 Schirmer Test Paper (OptiTech Eyecare, India) 
Schirmer test paper is a diagnostic sterile filter paper with gauge printed on the strip 
(Figure 3.7). It is used to measure basal tear production with instillation of local 
anesthesia. 
 
 
 
Figure 3.7 Schirmer Test Paper 
 
 
3.13 Medication 
3.13.1 Guttae Tropicamide 1% (Alcon Laboratories, USA) 
Topical tropicamdie 1% (Figure 3.8) is used for dilation of pupil for fundus examination. 
It is an anticholinergic drug which acts by blocking acetylcholine thus resulting in 
relaxation of iris sphincter muscle. The iris radial muscle which is innervated by 
adrenergic pathway is therefore unopposed and hence producing pupil dilatation. 
 
 
